Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Philogen SpA's Pre-Tax Income for the
six
months ended in Dec. 2025 was €275.5 Mil. Philogen SpA's Revenue for the
six
months ended in Dec. 2025 was €308.8 Mil. Therefore, Philogen SpA's pretax margin for the quarter that ended in Dec. 2025 was 89.20%.
The historical rank and industry rank for Philogen SpA's Pretax Margin % or its related term are showing as below:
MIL:PHIL'
s Pretax Margin % Range Over the Past 10 Years
Min: -610.58 Med: -22.55 Max: 82.75
Current: 82.75
MIL:PHIL's Pretax Margin % is ranked better than 97.57% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs MIL:PHIL: 82.75
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Philogen SpA Pretax Margin % Related Terms
Philogen SpA Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Philogen SpA's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Pretax Margin % of 89.20% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Philogen SpA and its competitors. According to the industry distribution chart, Philogen SpA ranks #23 out of 946 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Philogen SpA's Pretax Margin % too high?
Philogen SpA's current Pretax Margin % is 89.20%. Based on the distribution chart, Philogen SpA ranks #23 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #23 out of 946 companies for Pretax Margin %. This places Philogen SpA in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Philogen SpA and its competitors. Philogen SpA's current Pretax Margin % is 89.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.25 — trading 89.8% below its estimated fair value. The current Pretax Margin % is 89.20%. Philogen SpA's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Pretax Margin % is 89.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.25 is trading 89.8% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Pretax Margin %: 89.20%
GF Value™: €227.22 vs. price of €23.25 (89.8% below fair value)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score
Get the complete analysis for MIL:PHIL
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
